Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial
Table 2
Analyses of anthropometric parameters.
Secondary outcomes (Anthropometric parameters)
Period
Group
()
Placebo group ()
TJ001 group ()
Mean ± S.D.
()
Mean ± S.D.
()
Weight, kg
Baseline
—
—
0.5458
—
week 4
0.3272
week 8
0.3900
week 12
0.3080
0–12
0.0371
<0.0001
—
0.0708
ANOVA
visit X group interaction:
Body mass index (BMI), kg/cm2
Baseline
—
—
0.8598
—
week 4
0.5660
week 8
0.7407
week 12
0.5420
0–12
0.0061
<0.0001
—
0.1680
ANOVA
visit X group interaction:
Waist circumference (WC), cm
Baseline
—
—
0.6259
—
week 4
0.1932
week 8
0.3938
week 12
0.6056
0–12
0.010
<0.0001
—
0.7665
ANOVA
visit X group interaction:
Hip circumference (HC), cm
Baseline
—
—
0.7096
—
week 4
0.3027
week 8
0.4026
week 12
0.4330
0–12
0.0003
<0.0001
—
0.3183
ANOVA
visit X group interaction:
Waist/hip ratio (WHR)
Baseline
—
—
0.6934
—
week 4
0.4217
week 8
0.6775
week 12
0.4159
0–12
0.1307
0.0108
—
0.4058
ANOVA
visit X group interaction:
: A value for between-group comparison at each visit and visit X group interaction using ANOVA. (): A value for within-group comparison between baseline and 5th visit by paired -test. (): A value for between-group comparison after 12-week treatment using ANCOVA (baseline as covariate). 0–12: Changes between baseline and the 5th visit (after 12-week treatment). were considered statistically significant.